Purpose: To estimate the proportion of residents newly initiating long-acting opioids in comparison to residents initiating short-acting opioids and examine variation in long-acting opioid initiation by region and resident characteristics.
| INTRODUCTION
In the United States, the Centers for Disease Control and Prevention's (CDC) opioid prescribing guidelines for persons experiencing nonmalignant chronic pain (outside of the context of palliative or end-of-life care) warn that initiating long-acting opioids in individuals without sufficient opioid tolerance increases the risk of respiratory depression and death. [1] [2] [3] These risks may be higher among older adults living in nursing homes due to age-related physiologic changes, polypharmacy, and multimorbidity altering opioid pharmacokinetics and pharmacodynamics and subsequently increasing the risk of adverse events. [4] [5] [6] Globally, long-acting opioids are frequently prescribed in nursing homes to manage pain. In US nursing homes, 6% of all residents and 17.8% of residents prescribed any opioids received long-acting opioid prescriptions in 2012. 7 In other countries, long-acting opioids including fentanyl and buprenorphine are frequently prescribed in nursing homes (eg, Denmark: 18.7% 8 ; Norway:~15% 9 ; Australia:
18.3%). 10 However, little is known about how long-acting opioids are initiated in nursing homes, especially in comparison with alternative pharmacologic pain management strategies-such as initiating short-acting opioids.
In prior studies restricted to long-acting opioid initiators (ie, both naïve long-acting opioid initiators and prevalent opioid users later prescribed long-acting opioids), the proportion of residents beginning long-acting opioid therapy without any prior short-acting therapy ranged from 9% to 39%. [11] [12] [13] However, these studies provide limited information on the extent of this inappropriate prescribing practice by solely focusing on long-acting opioid initiation and excluding residents initiating only short-acting opioids. Short-acting opioids are prescribed to over 90% of opioid users in US nursing homes and are the recommended duration of action to initiate for residents requiring opioids for pain management. 1, 7 To further understand the magnitude of long-acting opioid initiation in this population, we leveraged a national data set of nursing home residents from 2011 to 2013 to examine the frequency of longacting opioid initiation among all residents initiating opioids and identify resident-level correlates and geographic variation of long-acting opioid initiation.
| METHODS

| Study design and data sources
We conducted a cross-sectional study comparing long-acting to shortacting opioid initiators by using national, routinely collected that provided data on resident characteristics and the geographic location of the nursing home. Assessments are conducted by registered nurses who consult the resident, the resident's medical record, their caregivers, and other nursing home staff. Assessments have demonstrated validity and reliability and include measures of demographics, pain, cognitive and physical functioning, and other measures. [14] [15] [16] These data were merged to Medicare Part D, an outpatient prescription drug insurance program used by >80% of nursing home residents. 17 Part D claims provided data on national drug codes, generic drug names, dosage strength, and days' supply that were used to identify opioid prescriptions.
| Analytic sample
We identified 182 735 fee-for-service Medicare beneficiaries (Part A/B/D coverage for ≥3 months; no Medicare Advantage) who were long-stay nursing home residents (≥90 consecutive days at the same nursing facility) and initiated a short-acting or long-acting opioid. We focused on long-stay nursing home residents because they generally require long-term assistance to manage their chronic disabilities. 18 We then applied several criteria to exclude (1) 19 because of different treatment guidelines for these populations, (6) those who were comatose, and (7) those missing data on resident characteristics. See Figure S1 for more detail.
| Opioid initiation
Opioid initiation was defined as the first Part D opioid prescription claim during follow-up with no prior opioid claims in the past 60 days; this lookback period was chosen to compare our results to prior studies. [11] [12] [13] Opioids were classified by their duration of action (short-acting and long-acting). Short-acting opioids including products combined with acetaminophen or nonsteroidal antiinflammatory drugs included codeine, dihydrocodeine hydrocodone, hydromorphone, fentanyl citrate, meperidine, morphine, oxycodone, nalbuphine, tapentadol, and tramadol. Long-acting opioids included hydromorphone extended release (ER), methadone, morphine ER, oxycodone ER, tapentadol ER, and tramadol ER.
Our primary outcome was the proportion of opioid initiators prescribed long-acting opioids. The numerator was the number of
KEY POINTS
• In the United States, 2.2% of long-stay residents initiating opioids during 2011 to 2013 were prescribed long-acting opioids.
• Geographic variation in proportion of initiators prescribed long-acting opioids ranged from 0.6% in Louisiana to 7.5% in South Dakota.
• Resident characteristics were associated with initiating long-acting opioids including older age, being a woman, being non-Hispanic white, being severely cognitively or physically impaired, and having staff-reported or selfreported pain before opioid initiation.
• This study provides evidence that long-acting opioid initiation is lower than previously documented in nursing homes, although variation by region and resident characteristics suggests that improvements are possible.
residents newly prescribed long-acting opioids; the denominator was the number newly prescribed any (long-acting or short-acting) opioids.
We also estimated the average daily dose based on all prescriptions filled on the index date in oral morphine equivalents (OMEs) by estimating the total OME dispensed (by multiplying the dosage strength by the quantity dispensed and OME conversion factor) 20 and then dividing by the total days' supply. Average daily doses were categorized as <50, 50 to 89, and ≥90 mg OME/day. 1
| Geographic variation
Long-acting opioids in nursing homes may vary by geographic region, as substantial variation in the quality of prescribing has been documented among older community-dwelling adults. 21, 22 We first examined geographic variation by state and then grouped residents into hospital referral regions (HRRs; n = 306) to examine variation within smaller regional health care markets (where each HRR has at least 1 hospital that performs both major cardiovascular procedures and neurosurgery). Data on HRRs were linked to our sample by using a publically available crosswalk provided by the Dartmouth Atlas Project based on residents' nursing home location. 8-12), and severe impairment (CPS: 5-6; BIMS: 0-7). 30 Physical limitations were categorized by using the MDS Activities of Daily Living Self-Performance Hierarchy Scale (range 0-6) as none/mild (0-2), moderate (3-4), and severe limitations (5-6). 31 Pain in the 5 days before the MDS assessment was based on resident self-report when the resident was capable of responding and staff assessment otherwise.
We classified residents as being in no pain (self-reported or staffassessed), having self-reported pain, or staff-assessed pain.
| Analysis
We estimated the overall proportion of opioid initiators prescribed long-acting opioids. We then examined the most commonly used medications and average daily dose by duration of action initiated and tabulated overall and stratum-specific estimates of the proportion of initiators prescribed long-acting opioids by state, HRR, and resident characteristics. To examine geographic variation, we grouped HRRs into quartiles of long-acting opioid initiation and created maps. Finally, we fit logistic models by using generalized estimating equations to estimate crude and adjusted odds ratios and 95% confidence intervals (CIs) between resident characteristics and initiating long-acting opioids. The models used an exchangeable correlation structure to account for clustering within facilities. Adjusted models included only the resident characteristics described previously; no other covariates were considered or tested for inclusion.
In sensitivity analyses, we examined the prevalence and correlates of long-acting opioid initiation after excluding younger Medicare ben- Oral morphine equivalents were estimated by multiplying the dosage strength in oral morphine equivalents (using conversion factors) by the quantity dispensed and dividing by days' supply of prescriptions dispensed on index date. The columns may not add to 100% because of rounding.
doses <50 mg OME/day (92.2% and 77.7% for those initiating longand short-acting opioids, respectively); 3.3% of long-acting and 8.5%
of short-acting opioid initiation were prescribed doses ≥90 mg OME/day.
By state, the crude proportion of opioid initiators prescribed longacting opioids ranged from 0.6% in Louisiana to 7.5% in South Dakota (Figure 1 ; 5th-95th percentiles: 0.6-6.4%). By HRR, the proportion receiving long-acting opioid prescriptions ranged from 0% in 16
unique HRRs to 9.5% in Great Falls, Montana (Figure 2 ; 5th-95th percentiles: 0%-5.1%). Long-acting prescribing among those initiating opioids was primarily concentrated in the Northeast and throughout the northern regions of the Midwest and West census regions. Conversely, long-acting opioids were sparingly initiated in the South (eg, Texas, Oklahoma, and Louisiana), although other regions such as southern California also had low prescribing.
When examining variation by resident characteristics, crude differences in the proportion of initiators prescribed long-acting opioids never exceeded 2% ( Sensitivity analyses excluding younger residents (<65 years) had little impact on the prevalence and correlates of long-acting opioid initiation (Table S1 ).
| DISCUSSION
In 2011 to 2013, the overwhelming majority of prescription opioids initiated in US nursing homes were short-acting opioids. For this particular aspect of opioid prescribing, nursing homes were largely aligned with the general CDC prescribing guidelines, 1 and the estimated 2.2%
initiating long-acting opioids (3977 initiators of long-acting opioids) between 2011 and 2013 are lower than previously reported. 12 However, we documented meaningful variation by region and resident characteristics, which may indicate that improvements are possible.
Further, the proportion initiating long-acting opioids was higher than reports from community-dwelling populations and raises additional questions on how long-acting opioids are initiated in frail elderly nursing home residents. 40 In contrast to prior studies, 11, 13 we found that most of long-acting opioid initiators were prescribed transdermal fentanyl. It is currently unclear why the proportion of long-acting initiators being prescribed fentanyl would increase given Food and Drug Administration and CMS warnings explicitly pertaining to fentanyl. We cannot rule out other explanations for the observed differences including different analytic samples (eg, restricting to those newly admitted to nursing homes) and studying different short-and long-acting opioids. . 35 Given that the proportion of initiators prescribed long-acting opioids is higher among older adults and other populations with a higher burden of painful comorbidities, it is possible that the risk of naively initiating long-acting opioids is higher in those with more severe pain. In nursing homes, this may be residents at the end of life (or perceived to be at the end of life), which is consistent with the positive associations we found between being prescribed a long-acting opioid and older age, cognitive impairment, physical limitations, and staff assessed pain. If this is the case, CDC prescribing guidelines may not be applicable because they were not intended for persons receiving palliative care. 1 Yet, even palliative care guidelines discourage initiating transdermal long-acting opioids as first line treatment when oral opioids can be used, 43 which was the most commonly initiated dosage form among long-acting opioid initiators in our study.
Further work is needed to understand why long-acting opioids are initiated with no prior opioid therapy-both within and outside of nursing homes.
When examining resident correlates of newly initiating longacting opioids, our results are largely consistent with a prior study despite different treatment contrasts. 12 Our prior work on the pharmacological management of nonmalignant pain suggests that non-White residents are less likely to receive scheduled analgesics and be prescribed opioids long-term in comparison with White residents. 7, 29 We are uncertain if similar mechanisms are driving the differences observed in this study because initiating long-acting opioids is contraindicated, whereas scheduled analgesics and long-term opioid use may be necessary for residents experiencing moderate to severe chronic pain. 4 The geographic variation observed at the state and HRR levels suggests that efforts to reduce long-acting opioid initiation in nursing homes may be more pressing in the Northeast and northernmost states in the Midwest and West. This is similar to trends of long-acting opioid prescribing in the broader US population in 2012, 44 although not all northern Midwest and Western states in the larger population were in the highest quartile of long-acting opioid prescribing. Similarly, many states with the lowest proportion of residents initiating longacting opioids also had low long-acting opioid prescribing in the general population (eg, California, Texas, and Louisiana). This variation raises further questions on how policies and laws regulating opioid prescribing, the prescribing culture, and other factors affect opioid use and initiation in nursing homes, as this may influence both resident safety and pain management in a population that has historically had their pain undertreated. [24] [25] [26] [27] [28] [29] Efforts to improve opioid prescribing in nursing homes must keep in mind the unique needs of residents, as opioids may often be the only treatment option because acetaminophen may be insufficient to manage moderate to severe pain and nonsteroidal antiinflammatory drugs have cardiovascular, renal, and other risks in older adults. 4, 45 Although certain aspects of opioid prescribing can likely be improved (eg, reducing the co-prescribing of opioids with other psychotropic medications), 7 they should be balanced against the palliative care needs of these residents. For example, we found that many residents initiated opioids at doses ≥50 mg OME/day, which is discouraged due to the strong dose-response relation between opioids and opioid-related adverse events (eg, falls/fractures and overdoses) 1 but may be necessary to manage pain if palliative care is the goal of treatment.
Strengths of this study include using a large, national sample during the height of US opioid prescribing (2011-2013). 46 Our study design also emulated the clinical decision-making process that a prescriber would make when beginning opioid therapy-whether to Claims also provided no data on how opioids were used to manage pain (ie, scheduled or as needed). We excluded residents receiving hospice care based on MDS assessments rather than hospice claims.
Although the potential for bias is limited given that MDS assessments are required when residents enroll in hospice, our estimates of long-term opioid initiation may be conservative if we failed to completely exclude residents in hospice and hospice enrollees predominantly initiated short-acting opioids. 48 In our adjusted statistical models, we included a limited number of resident characteristics that have been strongly associated with receiving pain management in nursing homes. 7, [24] [25] [26] [27] [28] [29] We cannot rule out residual or unmeasured confounding. Because we exclusively focused on long-stay residents, we could not comment on opioids initiated shortly after entering the nursing home. Finally, we relied on prescription claims from a single payer and could not account for stockpiled medications or medications obtained from sources other than Medicare Part D.
In conclusion, we found that most of residents initiate short-acting opioids instead of long-acting opioids and that the absolute number of residents initiating long-acting opioids is lower than previously documented. [11] [12] [13] Although further efforts to understand why longacting opioids are naively initiated are still needed due to its frequency in nursing homes versus community settings, 2,34,35 efforts to improve opioid prescribing in this care setting must consider the unique palliative care needs of these residents. Defined by using the Brief Interval for Mental Status (BIMS; range 0-15) when the resident was able to self-report and the Cognitive Performance Scale (CPS; range 0-6) otherwise: none/mild (CPS 0-2, BIMS 13-15), moderate (CPS 3-4, BIMS 8-12), and severe (BIMS 0-7, CPS 5-6).
d Defined by using the Minimum Data Set Activities of Daily Living Self-Performance Hierarchy Scale (range: 0-6): none/mild (0-2), moderate (3) (4) , and severe (5-6).
e Defined by using MDS 3.0 Section J: any self-reported pain in previous 5 days (J0300 indicated as "yes"),and any staff-assessed pain in previous 5 days (J0850 indicating staff-observed pain).
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